Nivorest 40 mg & 100 mg (Nivolumab) | Opdivo Alternative & Price Guide

Description

Nivorest is an intravenous immunotherapy containing nivolumab, the same active molecule sold under the brand name Opdivo. Everest Pharmaceuticals manufactures it in Bangladesh under WHO-GMP standards. It comes in two single-dose vial sizes, 40mg/4mL and 100mg/10mL, both at the same 10mg/mL concentration. The two sizes exist so that a prescribed dose can be made up with less wastage, not because they differ in strength.

Nivolumab does not act on cancer cells directly. It blocks a receptor called PD-1 on the surface of T-cells. Tumors use that receptor to signal immune cells to stand down, and blocking it allows T-cells that could already identify the cancer to resume attacking it.

One feature separates nivolumab from most other drugs in this class in day-to-day practice. It is frequently prescribed together with ipilimumab, a second immunotherapy that works on a different checkpoint. In advanced melanoma and in renal cell carcinoma, that pairing is a standard first-line approach rather than a fallback, and it changes both the infusion schedule and the monitoring your team will carry out.

If you are researching Nivorest as an alternative to the originator brand, one point needs stating plainly. Nivorest is not an FDA-approved or EMA-approved biosimilar. No biosimilar nivolumab has been approved in either market, because Opdivo remains under patent protection there. Production of patent-protected biologics in Bangladesh is permitted under the WTO’s TRIPS exemption for least-developed countries. We publish this here rather than leave you to discover it later.

Clinical Expert Insight

“Nivolumab and pembrolizumab work through the same receptor, but they occupy different places in my clinic. Nivolumab is the one I most often discuss alongside a second drug, ipilimumab, particularly in melanoma and kidney cancer.

That conversation has two halves and patients deserve both. The combination can achieve more than either agent alone. It also produces immune-related side effects more often, and more severely, than nivolumab by itself. Patients starting on the combination should hear that before their first infusion. Not afterwards, when a symptom has already appeared and they are trying to work out whether it matters.”

— Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center

Nivorest Uses and Clinical Safety Protocols

Precise Indications & Biomarkers

• Melanoma: unresectable or metastatic disease, given alone or with ipilimumab. Also approved as adjuvant treatment following complete surgical removal.
• Non-small cell lung cancer: metastatic disease after prior therapy, and as neoadjuvant treatment combined with platinum-doublet chemotherapy before surgery in resectable tumors.
• Renal cell carcinoma: advanced disease, as monotherapy after prior therapy or in first-line combination with ipilimumab or cabozantinib.
• Classical Hodgkin lymphoma: relapsed or refractory disease.
• Head and neck squamous cell carcinoma, urothelial carcinoma, hepatocellular carcinoma: each governed by its own line-of-therapy criteria.
• Esophageal, gastric and gastroesophageal junction cancers: generally in combination with chemotherapy or ipilimumab, with PD-L1 expression informing patient selection.
• Colorectal cancer with MSI-High or mismatch repair deficient status. This point separates nivolumab from pembrolizumab and is often misread. Pembrolizumab holds a tumor-agnostic approval covering any solid tumor with these markers. Nivolumab’s biomarker-based approval applies to colorectal cancer. If you have been told your tumor is MSI-High, ask your oncologist which of the two drugs your specific diagnosis qualifies for.

Mechanism of Action, Pharmacokinetics & Administration

Nivolumab binds the PD-1 receptor on T-cells and blocks its interaction with PD-L1 and PD-L2. T-cells already primed against the tumor stay active as a result.

Terminal half-life is approximately 25 days. That is why monotherapy infusions are spaced two to four weeks apart rather than weekly, and it is also why an immune-related side effect can appear months after a final infusion.

Other pharmacokinetic characteristics that shape treatment:

• Absorption: administered intravenously and therefore fully available in the bloodstream immediately. There is no absorption phase.
• Distribution: small volume of distribution, typical for a therapeutic antibody.
• Metabolism: cleared through the general protein breakdown pathways that handle every antibody in the body. Liver enzymes (CYP450) play no part. Hepatic and renal impairment therefore have limited effect on exposure.
• Immunogenicity: a proportion of patients develop antibodies against nivolumab during treatment. In pooled analysis these did not alter the drug’s pharmacokinetic profile or raise the rate of infusion reactions, and neutralizing antibodies were uncommon.

Administration. Nivorest is given as an intravenous infusion over approximately 30 minutes through an in-line filter, at a hospital or infusion center, by staff trained to administer it. It is never self-administered, and there is no missed-dose rule to memorize, since the infusion center holds the schedule.

Dosing depends on whether the drug is given alone or in combination:

• Monotherapy: 240mg every two weeks, or 480mg every four weeks. These flat doses replaced the older weight-based 3mg/kg regimen in most protocols.
• With ipilimumab: several induction cycles of the two drugs together, followed by a switch to nivolumab alone for maintenance. Induction length, dose and interval vary by indication and are set by the treating team.
• Neoadjuvant NSCLC: 360mg every three weeks alongside platinum-doublet chemotherapy for a defined number of cycles before surgery.

Adverse Event (AE) Management Table

Chemotherapy side effects tend to follow a pattern patients can anticipate: hair loss, low blood counts, nausea at predictable points in the cycle. Nivolumab behaves differently. Because it works by reactivating the immune system, the principal risk is that the immune system inflames healthy tissue, and this can happen in the lungs, bowel, liver, thyroid, kidneys or skin before you would notice anything yourself. Your team will check liver enzymes, creatinine and thyroid function at the start of treatment and at intervals throughout it.

The figures below reflect nivolumab given as a single agent. Combination treatment with ipilimumab raises both the frequency and the severity of these reactions. Anyone starting the combination should be counselled on that separately, since the monitoring intensity differs.

Table-01: Immune-Mediated Adverse Event Management (monotherapy figures)

Across all categories, treatment resumes only once symptoms settle to Grade 1 or lower and corticosteroids taper down over at least a month. Where that taper cannot be achieved, treatment is usually stopped permanently. Median time to onset for pneumonitis in pooled data was around three and a half months, with cases reported from the first day of treatment out to nearly two years, which is the clearest illustration of why monitoring does not stop after the early cycles.

Clinical Efficacy: The CheckMate Benchmarks

• Advanced melanoma (CheckMate-067, NCT01844505). A three-arm Phase III trial comparing nivolumab alone, ipilimumab alone, and the two combined. The combination produced the strongest outcomes of the three arms, alongside a higher rate of serious immune-related adverse events than either single agent. This trade-off is the reason combination therapy is a discussion rather than a default.
• Renal cell carcinoma, previously treated (CheckMate-025). Established a survival benefit for nivolumab monotherapy over everolimus in advanced disease.
• Renal cell carcinoma, first line (CheckMate-214). Supported nivolumab plus ipilimumab as a first-line option in intermediate and poor-risk advanced disease.
• Non-small cell lung cancer (CheckMate-017 and CheckMate-057). Established benefit over docetaxel in previously treated squamous and non-squamous NSCLC respectively.
• Adjuvant melanoma (CheckMate-238). Supported use after complete surgical resection in high-risk disease.

Nivolumab’s label spans more indications than any oral product in our catalogue, and each approval rests on its own pivotal trial rather than shared data. The FDA approval history page lists them in full.

Interaction & Precaution Matrix

Nivolumab has no classic CYP450-mediated drug interactions. Several treatment-level considerations still matter clinically.

Table-02: Treatment-Level Interaction Considerations

Precautions & Special Populations

• Pregnancy. Nivolumab can cause fetal harm based on its mechanism of action. Patients of reproductive potential should use effective contraception during treatment and for a defined period afterwards.
• Lactation. It is not known whether nivolumab passes into breast milk. Breastfeeding is not recommended during treatment or for a period after the final dose.
• Hepatic and renal impairment. Mild to moderate impairment does not usually require a dose change, for the reason set out in the pharmacokinetics section above. Data in severe impairment remains limited, and these patients need closer monitoring.
• Prior transplant history. Requires a joint decision between the oncology and transplant teams before starting.
• Storage. Nivorest must be kept refrigerated at 2°C to 8°C for its entire journey. It must not be frozen or shaken. Along with Pemrest, it is one of the few products in our catalogue carrying a continuous cold-chain requirement; the oral medicines we ship tolerate room temperature.

Certified Quality & International Distribution

Nivorest (Everest) and Opdivo (Originator) Compared

The table below states only what can be verified today.

Table-03: Product Comparison

Everest Pharmaceuticals Manufacturing

Everest Pharmaceuticals produces Nivorest in a WHO-GMP certified facility with dedicated biologics handling.

Global Access: Named Patient Program (NPP)

Patients in regions where Nivorest is not locally registered may still access it under Named Patient or personal-use importation rules.

• Prescription. A valid prescription and treatment summary from your treating oncologist.
• Documentation. A Letter of Medical Necessity and patient identification.
• Import permit. Our team handles the personal-use import permit application with your local drug authority.
• Logistics. Because Nivorest is a refrigerated biologic, shipment goes through cold-chain-verified couriers with continuous temperature monitoring rather than the standard timeline used for our oral medicines.

Frequently Asked Questions (FAQs)